Qiagen stock steadies near 43 dollars as latest quarter shows modest growth

Published on 09/02/2026 at 16:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Qiagen stock is trading in the low to mid 40 dollar range while the diagnostics group reports slightly higher earnings and revenue in its most recent quarter, giving investors a stable picture of profitability and analyst expectations.

Qiagen N.V. (NL0012169213) Bauhaus-Poster mit stilisierter DNA-Doppelhelix in kräftigen Primärfarben und geometrischer Komposition, Illustration mit AI erstellt.

Qiagen stock (ISIN NL0012169213) is quoted around 43.23 USD as of August 31, 2026 on its New York Stock Exchange listing, corresponding to a market capitalization of 8.926 billion USD and underlining its status as a mid-cap diagnostics player for investors tracking valuation levels in the sector according to a market-data overview.

Latest quarterly figures and profit trends

According to an earnings summary compiled by MarketBeat and cited in the same analysis, Qiagen most recently reported quarterly earnings per share of 0.62 USD on revenue of 535.04 million USD for a quarter that ended within the last 12 months, making this the most recent available set of figures for the company’s operations and profitability in 2026 or late 2025.

The MarketBeat detail shows that these results modestly beat consensus expectations, with analysts having forecast 0.60 USD earnings per share and 527.50 million USD in revenue for the quarter, so Qiagen exceeded the earnings projection by 0.02 USD per share and the revenue estimate by around 7.54 million USD according to the same dataset.

In that latest quarter, Qiagen achieved a net margin of 19.49 percent and a return on equity of 14.47 percent, indicating that the company converted almost one fifth of its sales into net income while generating mid-teens returns on shareholder capital in the most recently reported period, numbers that are central for investors evaluating the quality of the business model.

Growth comparison and analyst consensus

The quarterly comparison referenced by the MarketBeat overview highlights that earnings per share in the latest period rose from 0.60 USD a year earlier to 0.62 USD, an increase of 0.02 USD per share, while revenue grew to 535.04 million USD from a slightly lower base, described as an increase of 0.2 percent year on year, underscoring that profit growth currently outpaces the very modest top-line expansion.

Alongside these operating trends, analysts have maintained a cautious stance: the consensus overview compiled by MarketBeat on September 1, 2026 assigns Qiagen stock an average 12-month price target of 43.93 USD and categorizes the shares with a hold rating, only slightly above the share price snapshot of 43.35 USD used in that analysis and thus signaling limited implied upside at present.

For investors, this combination of nearly stable revenue, slightly higher earnings per share and robust net margin means that Qiagen is primarily a story of profitability discipline rather than fast growth, with the market currently valuing the company close to the analyst target range and leaving future quarterly results as the main potential catalyst for a re-rating.

Go deeper

More on Qiagen fundamentals and stock performance

Investors who want to track Qiagen stock and the company’s latest financial figures can find additional details, longer-term charts and upcoming corporate dates in the dedicated topic area and on the company’s investor relations pages.

Qiagen stock on ad-hoc-news.de Investor Relations

Representative product in sample preparation

Qiagen is known worldwide for its nucleic acid sample preparation technologies, with a representative product line being its QIAcube automated sample processing instruments and associated kits used to purify DNA and RNA for downstream applications in diagnostics and research labs; these solutions contribute to the revenue base that reached 535.04 million USD in the latest reported quarter and help explain why the company can sustain a net margin close to 20 percent in its core activities.

Stock level and trading perspective

As of August 31, 2026, Qiagen stock traded at 43.23 USD on the New York Stock Exchange under the ticker QGEN, with the pricing snapshots in late August and early September placing the shares in the low to mid 40 USD range between roughly 43.23 USD and 43.39 USD, a band that investors in Germany can monitor via secondary quotations such as a 37.70 EUR Tradegate level reported around 08:35 on September 2, 2026, keeping the valuation consistent across markets.